{"name":"Alzheon Inc.","slug":"alzheon-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"ALZ-801","genericName":"ALZ-801","slug":"alz-801","indication":"Alzheimer's disease","status":"phase_2"},{"name":"Experimental: ALZ-801","genericName":"Experimental: ALZ-801","slug":"experimental-alz-801","indication":"Early symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia stage)","status":"phase_3"}]}],"pipeline":[{"name":"ALZ-801","genericName":"ALZ-801","slug":"alz-801","phase":"phase_2","mechanism":"ALZ-801 is a dual A beta 42 and A beta 40 inhibitor.","indications":["Alzheimer's disease"],"catalyst":""},{"name":"Experimental: ALZ-801","genericName":"Experimental: ALZ-801","slug":"experimental-alz-801","phase":"phase_3","mechanism":"ALZ-801 is a small-molecule inhibitor of tau protein aggregation that crosses the blood-brain barrier to reduce pathological tau accumulation in the brain.","indications":["Early symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia stage)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0wJBVV95cUxQNjZkbzlSbGxHRUFBRy1qcnJVREpTcEVJcnVrQ2RLVGs5ZVRORDUwamhzWUZJZEhxYV84ZVRfS1VXam4wcDQzbGtNQ1g0ZkZmZi1BTXBmZlNuVkJ6TElUZWVJM1k5ZGNJZGVFQ05ieXVwQzVWVDM0UUVQRFlDSnpFUm1fbU42LTlfVjJQSWZMRWpmM3FYUER1cUctdlpaMzJ3a1VwVkZYUTN0di1Ga1laeWc4azRXN2VEX1V0MDJFc1g4M25URWZPaDhwWW1SWEptaHhGUEZ3eWJ1YUp1ZjMxOHlPNTlxYTRTZFo2Q1RublE5cFpfU2RLUC15Q2pBaTNjSUZfTzR1czk4eFFJVGZFcnFNTE5LOF9nbGEta2U4Q1Fjb1NJUTNMWlU1Q3lTZjNIQjRjdEpsZmltSDYxZlg1alk3UnRFc3hDdkh4VDB6UzJ2aVU?oc=5","date":"2025-12-02","type":"pipeline","source":"Business Wire","summary":"Alzheon Announces Peer-Reviewed Publication Providing Evidence for Hippocampal Volume as Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Alzheimer’s Disease - Business Wire","headline":"Alzheon Announces Peer-Reviewed Publication Providing Evidence for Hippocampal Volume as Surrogate Marker for Clinical B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE9QeXh5bTJ5X3FSajd5QmhCNnZtakVOUVdSY1Z2eV9aZUtRMnFKNExidHZqaXM3OW92Rjlac3BLZko1QW1EaHAzSzB1S0MwdlFaVkw3OTd5ZEEtemlqekttbjhqb2RXUFc2QjcxTGVGcUd0cmZadTR5SA?oc=5","date":"2025-11-25","type":"pipeline","source":"labiotech.eu","summary":"11 neuroscience biotech companies you should know about - labiotech.eu","headline":"11 neuroscience biotech companies you should know about","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQVTJLckpxTXhvUVFYMjVUaW1qUVlwX3FwTnRhTXk4YTZyYzhLMGVRbXRVRWRHNUYxVjZXSElvSEtvdXk0ck9hcEIzVUo5RmtQSmZab2FCQVl3ZzJoLXRxb2h0aEVMendJN1RjYVNJbUgwQXdjZDFSVTRKOWItZ3drT1F0TndJa2tNV1MxcjBvSlNnc0c0OEtYTEJJbUNJUDRQTGw4TlM3NjhydzZqMHJIYzloRWg?oc=5","date":"2025-08-13","type":"pipeline","source":"PR Newswire UK","summary":"Alzheimer's DMT Market to Grow at 67.8% CAGR Through 2030 - PR Newswire UK","headline":"Alzheimer's DMT Market to Grow at 67.8% CAGR Through 2030","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPUU01cVQ4V1BycERreHRWbzRaRGpKakNWQVk2TDdEOGFCR25QZ3NBdlNnU0tJc1R5TkZDOUtMY0VDSm40NnNwVmFfS2JvbV9yYWdyT0lPVjNCSV9uZVRSbW9NZko5cGYwS01nYkhmaU1EODhzR0NFRE8teVVmUW5SdmhOYmVuUDc5?oc=5","date":"2025-06-23","type":"pipeline","source":"Yahoo Finance","summary":"[Latest] Global Alzheimer’s Drug Market Size/Share Worth USD 19.3 Billion by 2034 at a 13.03% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth R","headline":"[Latest] Global Alzheimer’s Drug Market Size/Share Worth USD 19.3 Billion by 2034 at a 13.03% CAGR: Custom Market Insigh","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPZUZXS0FybHRkdlRJTThQNWEzYkxSYmtDTXVXQnljY3pLUnlkYTluam9ZczJ5UG56ektHb0RLZXVuazI1RFJZQXFWeE51QUtmRy1zNks5N1lOaHQ2aC1uSUV6LThlZGlOR1VpT25KR1JqLV9OMElZT25nYjRHdjlzcm5Uei1ERlZPeVVvd1l3MW5QcFJQVHNZ?oc=5","date":"2025-06-16","type":"pipeline","source":"Grand View Research","summary":"UK Alzheimer’s Therapeutics Market | Industry Report 2030 - Grand View Research","headline":"UK Alzheimer’s Therapeutics Market | Industry Report 2030","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPTnVoVWpoZ29zRUNfUzAwYVNOY1VFSE9LZkhyNkl1Yl84ZHlIZlBSM24tajNvemFENUdiaGVPNVQ1ZldGdUdjV3RsUURzTFlxbnFKWGRaWjJhYlRpNnNYOXcwR3RGc3RwTTVFaW12cXRSZGVCRnN2MlFYSzJMb2ZxbVZlT1VKT3BialE?oc=5","date":"2025-04-11","type":"trial","source":"Clinical Trials Arena","summary":"Alzheon’s Alzheimer’s pill fails in Phase III trial - Clinical Trials Arena","headline":"Alzheon’s Alzheimer’s pill fails in Phase III trial","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxOV1dWeWVDcmdQMVNKa2hpZnJDcGNXYVVJOWd5QTZPTXlOTE94Z1pFMk03Q3RqOVFIdVpTSUZsa3h5V05iSkZ3X0gxM1hVYWVCUkdybFZsczRzeXA5RGs5YWdpTGVGRkc0b01qcnlsZjRtMWlsYTdXcDJta0RuRkRwQQ?oc=5","date":"2025-04-11","type":"trial","source":"pharmaphorum","summary":"Alzheon Alzheimer's hopes dented by trial readout - pharmaphorum","headline":"Alzheon Alzheimer's hopes dented by trial readout","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQcklXejdkZjlsalYxbGV0dnh4enhDSzJqNjBJS0ZhTHJwUktxMzFPRTlzYmlCMUl5OHpGb3V3OEVyR1NSQjdSb0psU0VrQ1h2SVp2OWxPa05BUlpvajYzVG9BOVEzbFlmTDVjQ2NrOGhhZFZsRHZWY2FzX0ZuWGJnR25Ja21PWFdoTVoydHlpX1pya09KX3FkZ3c1bUVBS2F1UzNwLWNHUWtMTzlyak80?oc=5","date":"2025-04-10","type":"trial","source":"MedCity News","summary":"Alzheon’s Precision Medicine Approach to Resurrect an Alzheimer’s Drug Fails Pivotal Study - MedCity News","headline":"Alzheon’s Precision Medicine Approach to Resurrect an Alzheimer’s Drug Fails Pivotal Study","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQSkVXMFJJeElfZWdwcUxGM0lGcVZ5S3RDakFuckh0NTdDazlaYXJjVHVRa1A2T0FnQkRVWDlrbmlnQ2dRbzQ4MjlCVFRGVngybG9sX2ZjNDNtZ3MwRlRmMkt3M1dsZ3pkcF9SeHYwd2dUYXJvbjV3OVc1MFFOMEliNm96bXd3OExob2ItUkdQc240T2RneVphUkdUemdzN1hLazk0VnVn?oc=5","date":"2025-04-10","type":"trial","source":"BioWorld News","summary":"Alzheon’s lead candidate misses a phase III in early Alzheimer’s - BioWorld News","headline":"Alzheon’s lead candidate misses a phase III in early Alzheimer’s","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE92RVh5dThPZjFERlhrVkM0UkFRRWtnSjhtUmQzcDRTV1B0YnZXNUs5ZS1fRkh0S2UzaVBERElWRUJ1WlI5RmJpaVlBXzhnV1dwMlczVnc2YzdXMnlHWnN5VkZ5bFh0LUk4bmdON0o1NmNWaFBYdm5BbjcwUXM?oc=5","date":"2024-10-01","type":"pipeline","source":"Wiley","summary":"Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease - Wiley","headline":"Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQeDVMZDhBXzRwcjRPSjBzbmk2UE1Wb1pmTXFObnk3Zk9td2NXdDBxQ2VZYzZtb1Bkd0xlR29pQ216OGpzbVV0Q01fa3ZUd0FPNnFnbUJVWVI3a0t0TkhEdEhUemhMMWgtSms3bTIzbjNNbVFYTFk2VDMxMi1NN2RRREo0SkRDTWxMTEQ2Ti1PV21FVlBoc2RfXzlIWEZTWmppeHBVTkZleVptQ0FRZFZIS3VBWWs?oc=5","date":"2024-06-12","type":"pipeline","source":"Genetic Engineering and Biotechnology News","summary":"Alzheimer’s Drug Developer Alzheon Closes $100M Series E Financing - Genetic Engineering and Biotechnology News","headline":"Alzheimer’s Drug Developer Alzheon Closes $100M Series E Financing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNdnppbkFqU2J1QWFFYXhVZzFTQ2llbnpuWE9pcFBqZHp1Y2FuQWdvZnVSWWNqYzNXQUx6QThtZ1o5WkVKak5wSUV2MVl4SnhmOE9wb2oyUFR1ZWxnaTBJSHgyZ0lJTUJXYUhMQV9IbDFqbzZSMHprVUYzS2JoaWF1Y1VPSkpFMUtnTnlGZjdiRW1KV256?oc=5","date":"2024-06-12","type":"pipeline","source":"citybiz","summary":"Alzheon Appoints Gino Santini to Board of Directors - citybiz","headline":"Alzheon Appoints Gino Santini to Board of Directors","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":1,"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}